Review



ccr2i rs504393  (Tocris)


Bioz Verified Symbol Tocris is a verified supplier
Bioz Manufacturer Symbol Tocris manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Tocris ccr2i rs504393
    Human and murine PDAC tumours demonstrate myeloid substitution following bone marrow cell targeted therapies, which is overcome by combined CCR2 plus CXCR2 blockade. (A) Comparison total PDAC-infiltrating CXCR2 + TAN was assessed by flow cytometry from matched FNA tumour biopsies at baseline following treatment with an orally dosed, small molecule <t>CCR2i</t> (blue) in combination with FOLFIRINOX (n=6 matched specimens). (B) Absolute number of CXCR2 + TAN per gram of tissue (×10 5 ) was assessed by flow cytometry from CCR2 −/− and wild-type mice treated with vehicle alone (left) or in combination with FOLFIRINOX (right) 25 days following orthotopic KCKO tumour implantation (n=5–6 mice/group). (C) Absolute number of CXCR2 + TAN (Left) and CCR2+ TAM (Right) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade alone (n=12 mice/group). (D) Absolute number of CXCR2+ TAN (Right) and CCR2 + TAM (Left) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade in combination with FOLFIRINOX chemotherapy (n=9 mice/group). (E) Total tumour-infiltrating myeloids was assessed by flow cytometry and represented as percentage change from vehicle treated controls following chemokine receptor blockade alone and in combination with FOLFIRINOX (n=9–12 mice/group). (F) Orthotopic KCKO tumour weights following 25 days of treatment with chemokine receptor blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=9 mice/group). (G) Survival analysis of KPC orthotopic tumour-bearing mice treated with FOLFIRINOX alone and in combination with PF-04136309 (CCR2i) or CXCR2i (n=10–15 mice per group). One-way ANOVA and two-tailed paired, for matched samples, or unpaired t-test were used to calculate P values. For survival analysis, P values were obtained by the log-rank (Mantel-Cox) test. *P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAM, tumour-associated macrophages; TAN, tumour-associated neutrophils.
    Ccr2i Rs504393, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 129 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ccr2i rs504393/product/Tocris
    Average 95 stars, based on 129 article reviews
    ccr2i rs504393 - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "Targeting both tumour-associated CXCR2 + neutrophils and CCR2 + macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma"

    Article Title: Targeting both tumour-associated CXCR2 + neutrophils and CCR2 + macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

    Journal: Gut

    doi: 10.1136/gutjnl-2017-313738

    Human and murine PDAC tumours demonstrate myeloid substitution following bone marrow cell targeted therapies, which is overcome by combined CCR2 plus CXCR2 blockade. (A) Comparison total PDAC-infiltrating CXCR2 + TAN was assessed by flow cytometry from matched FNA tumour biopsies at baseline following treatment with an orally dosed, small molecule CCR2i (blue) in combination with FOLFIRINOX (n=6 matched specimens). (B) Absolute number of CXCR2 + TAN per gram of tissue (×10 5 ) was assessed by flow cytometry from CCR2 −/− and wild-type mice treated with vehicle alone (left) or in combination with FOLFIRINOX (right) 25 days following orthotopic KCKO tumour implantation (n=5–6 mice/group). (C) Absolute number of CXCR2 + TAN (Left) and CCR2+ TAM (Right) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade alone (n=12 mice/group). (D) Absolute number of CXCR2+ TAN (Right) and CCR2 + TAM (Left) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade in combination with FOLFIRINOX chemotherapy (n=9 mice/group). (E) Total tumour-infiltrating myeloids was assessed by flow cytometry and represented as percentage change from vehicle treated controls following chemokine receptor blockade alone and in combination with FOLFIRINOX (n=9–12 mice/group). (F) Orthotopic KCKO tumour weights following 25 days of treatment with chemokine receptor blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=9 mice/group). (G) Survival analysis of KPC orthotopic tumour-bearing mice treated with FOLFIRINOX alone and in combination with PF-04136309 (CCR2i) or CXCR2i (n=10–15 mice per group). One-way ANOVA and two-tailed paired, for matched samples, or unpaired t-test were used to calculate P values. For survival analysis, P values were obtained by the log-rank (Mantel-Cox) test. *P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAM, tumour-associated macrophages; TAN, tumour-associated neutrophils.
    Figure Legend Snippet: Human and murine PDAC tumours demonstrate myeloid substitution following bone marrow cell targeted therapies, which is overcome by combined CCR2 plus CXCR2 blockade. (A) Comparison total PDAC-infiltrating CXCR2 + TAN was assessed by flow cytometry from matched FNA tumour biopsies at baseline following treatment with an orally dosed, small molecule CCR2i (blue) in combination with FOLFIRINOX (n=6 matched specimens). (B) Absolute number of CXCR2 + TAN per gram of tissue (×10 5 ) was assessed by flow cytometry from CCR2 −/− and wild-type mice treated with vehicle alone (left) or in combination with FOLFIRINOX (right) 25 days following orthotopic KCKO tumour implantation (n=5–6 mice/group). (C) Absolute number of CXCR2 + TAN (Left) and CCR2+ TAM (Right) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade alone (n=12 mice/group). (D) Absolute number of CXCR2+ TAN (Right) and CCR2 + TAM (Left) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade in combination with FOLFIRINOX chemotherapy (n=9 mice/group). (E) Total tumour-infiltrating myeloids was assessed by flow cytometry and represented as percentage change from vehicle treated controls following chemokine receptor blockade alone and in combination with FOLFIRINOX (n=9–12 mice/group). (F) Orthotopic KCKO tumour weights following 25 days of treatment with chemokine receptor blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=9 mice/group). (G) Survival analysis of KPC orthotopic tumour-bearing mice treated with FOLFIRINOX alone and in combination with PF-04136309 (CCR2i) or CXCR2i (n=10–15 mice per group). One-way ANOVA and two-tailed paired, for matched samples, or unpaired t-test were used to calculate P values. For survival analysis, P values were obtained by the log-rank (Mantel-Cox) test. *P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAM, tumour-associated macrophages; TAN, tumour-associated neutrophils.

    Techniques Used: Comparison, Flow Cytometry, Two Tailed Test



    Similar Products

    ccr2i rs504393  (Tocris)
    95
    Tocris ccr2i rs504393
    Human and murine PDAC tumours demonstrate myeloid substitution following bone marrow cell targeted therapies, which is overcome by combined CCR2 plus CXCR2 blockade. (A) Comparison total PDAC-infiltrating CXCR2 + TAN was assessed by flow cytometry from matched FNA tumour biopsies at baseline following treatment with an orally dosed, small molecule <t>CCR2i</t> (blue) in combination with FOLFIRINOX (n=6 matched specimens). (B) Absolute number of CXCR2 + TAN per gram of tissue (×10 5 ) was assessed by flow cytometry from CCR2 −/− and wild-type mice treated with vehicle alone (left) or in combination with FOLFIRINOX (right) 25 days following orthotopic KCKO tumour implantation (n=5–6 mice/group). (C) Absolute number of CXCR2 + TAN (Left) and CCR2+ TAM (Right) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade alone (n=12 mice/group). (D) Absolute number of CXCR2+ TAN (Right) and CCR2 + TAM (Left) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade in combination with FOLFIRINOX chemotherapy (n=9 mice/group). (E) Total tumour-infiltrating myeloids was assessed by flow cytometry and represented as percentage change from vehicle treated controls following chemokine receptor blockade alone and in combination with FOLFIRINOX (n=9–12 mice/group). (F) Orthotopic KCKO tumour weights following 25 days of treatment with chemokine receptor blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=9 mice/group). (G) Survival analysis of KPC orthotopic tumour-bearing mice treated with FOLFIRINOX alone and in combination with PF-04136309 (CCR2i) or CXCR2i (n=10–15 mice per group). One-way ANOVA and two-tailed paired, for matched samples, or unpaired t-test were used to calculate P values. For survival analysis, P values were obtained by the log-rank (Mantel-Cox) test. *P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAM, tumour-associated macrophages; TAN, tumour-associated neutrophils.
    Ccr2i Rs504393, supplied by Tocris, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ccr2i rs504393/product/Tocris
    Average 95 stars, based on 1 article reviews
    ccr2i rs504393 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    Human and murine PDAC tumours demonstrate myeloid substitution following bone marrow cell targeted therapies, which is overcome by combined CCR2 plus CXCR2 blockade. (A) Comparison total PDAC-infiltrating CXCR2 + TAN was assessed by flow cytometry from matched FNA tumour biopsies at baseline following treatment with an orally dosed, small molecule CCR2i (blue) in combination with FOLFIRINOX (n=6 matched specimens). (B) Absolute number of CXCR2 + TAN per gram of tissue (×10 5 ) was assessed by flow cytometry from CCR2 −/− and wild-type mice treated with vehicle alone (left) or in combination with FOLFIRINOX (right) 25 days following orthotopic KCKO tumour implantation (n=5–6 mice/group). (C) Absolute number of CXCR2 + TAN (Left) and CCR2+ TAM (Right) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade alone (n=12 mice/group). (D) Absolute number of CXCR2+ TAN (Right) and CCR2 + TAM (Left) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade in combination with FOLFIRINOX chemotherapy (n=9 mice/group). (E) Total tumour-infiltrating myeloids was assessed by flow cytometry and represented as percentage change from vehicle treated controls following chemokine receptor blockade alone and in combination with FOLFIRINOX (n=9–12 mice/group). (F) Orthotopic KCKO tumour weights following 25 days of treatment with chemokine receptor blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=9 mice/group). (G) Survival analysis of KPC orthotopic tumour-bearing mice treated with FOLFIRINOX alone and in combination with PF-04136309 (CCR2i) or CXCR2i (n=10–15 mice per group). One-way ANOVA and two-tailed paired, for matched samples, or unpaired t-test were used to calculate P values. For survival analysis, P values were obtained by the log-rank (Mantel-Cox) test. *P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAM, tumour-associated macrophages; TAN, tumour-associated neutrophils.

    Journal: Gut

    Article Title: Targeting both tumour-associated CXCR2 + neutrophils and CCR2 + macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma

    doi: 10.1136/gutjnl-2017-313738

    Figure Lengend Snippet: Human and murine PDAC tumours demonstrate myeloid substitution following bone marrow cell targeted therapies, which is overcome by combined CCR2 plus CXCR2 blockade. (A) Comparison total PDAC-infiltrating CXCR2 + TAN was assessed by flow cytometry from matched FNA tumour biopsies at baseline following treatment with an orally dosed, small molecule CCR2i (blue) in combination with FOLFIRINOX (n=6 matched specimens). (B) Absolute number of CXCR2 + TAN per gram of tissue (×10 5 ) was assessed by flow cytometry from CCR2 −/− and wild-type mice treated with vehicle alone (left) or in combination with FOLFIRINOX (right) 25 days following orthotopic KCKO tumour implantation (n=5–6 mice/group). (C) Absolute number of CXCR2 + TAN (Left) and CCR2+ TAM (Right) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade alone (n=12 mice/group). (D) Absolute number of CXCR2+ TAN (Right) and CCR2 + TAM (Left) per gram of tumour (×10 5 ) was assessed by flow cytometry following 25 days of treatment with chemokine blockade in combination with FOLFIRINOX chemotherapy (n=9 mice/group). (E) Total tumour-infiltrating myeloids was assessed by flow cytometry and represented as percentage change from vehicle treated controls following chemokine receptor blockade alone and in combination with FOLFIRINOX (n=9–12 mice/group). (F) Orthotopic KCKO tumour weights following 25 days of treatment with chemokine receptor blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=9 mice/group). (G) Survival analysis of KPC orthotopic tumour-bearing mice treated with FOLFIRINOX alone and in combination with PF-04136309 (CCR2i) or CXCR2i (n=10–15 mice per group). One-way ANOVA and two-tailed paired, for matched samples, or unpaired t-test were used to calculate P values. For survival analysis, P values were obtained by the log-rank (Mantel-Cox) test. *P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAM, tumour-associated macrophages; TAN, tumour-associated neutrophils.

    Article Snippet: The CCR2i RS504393 (Tocris) was given subcutaneously (SQ) at a dose of 5 mg/kg twice per day or PF-04136309 (Pfizer) at a dose of 100 mg/kg given SQ twice daily.

    Techniques: Comparison, Flow Cytometry, Two Tailed Test